Astellas names SVP and head of medical affairs Americas

12 May 2017

Japan’s Astellas Pharma (TYO: 4503) has promoted Shontelle Dodson to senior vice president and head of medical affairs Americas, effective May 15, 2017. Ms Dodson previously served as vice president of medical excellence within the global medical affairs organization.

"Shontelle has been an integral and formative leader in the building and evolution of the Medical Affairs organization at Astellas," said Charlotte Kremer, executive vice president and head, Medical Affairs, Astellas, adding: "I'm confident she will make an immediate and positive impact on both the team in the Americas, as well as the patients and partners we serve."

In her new role, Ms Dodson will report directly to Dr Kremer and assume overall responsibility for the strategic direction of the medical affairs Americas organization, including continued medical support of in-line products, late-stage development compounds and ongoing business evolution across the region.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK